Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: KalVista Pharma

Market Cap 1.44B 1.25B 1.16B 1.09B 2.04B 136B 2.05B 13.77B 5.34B 66.76B 5.4B 5.28B 232B P/E 2026 *
-32.3x
P/E 2027 * 15.8x
Enterprise Value 1.3B 1.13B 1.05B 980M 1.84B 122B 1.85B 12.42B 4.81B 60.2B 4.87B 4.76B 209B EV / Sales 2026 *
5.94x
EV / Sales 2027 * 4.1x
Free-Float
-
Yield 2026 *
-
Yield 2027 * -
1 day+0.04%
Current month+0.48%
1 month+0.71%
3 months+58.82%
6 months+77.28%
Current year+67.18%
1 month 26.77
Extreme 26.77
27
Current year 14.22
Extreme 14.22
27
1 year 9.83
Extreme 9.83
27
3 years 7.21
Extreme 7.21
27
5 years 4.12
Extreme 4.12
28.65
10 years 0
Extreme 0
45
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 66 01/11/2016
Chief Executive Officer 61 06/03/2024
President - 11/06/2026
Director TitleAgeSince
Chairman - 11/06/2026
Date Insider Type Main position Quantity % Market Cap.
06-11Issuer sale

Director

-67,000 0.1326%
06-11Issuer sale

Chief Operating Officer

-149,000 0.2948%
06-11Issuer sale

Chief Financial Officer

-270,411 0.5350%

Financials

2026 *2027 *
Net sales 218M 190M 176M 165M 309M 20.58B 311M 2.09B 810M 10.13B 819M 801M 35.17B 351M 306M 283M 265M 497M 33.08B 500M 3.36B 1.3B 16.28B 1.32B 1.29B 56.54B
Net income -71.87M -62.66M -58.03M -54.33M -102M -6.78B -103M -688M -267M -3.34B -270M -264M -11.59B 36.3M 31.65M 29.31M 27.44M 51.46M 3.43B 51.77M 348M 135M 1.69B 136M 133M 5.85B
Net Debt -141M -123M -114M -107M -200M -13.33B -202M -1.35B -525M -6.56B -530M -519M -22.79B -
Logo KalVista Pharma
KalVista Pharmaceuticals, Inc. is a global pharmaceutical company. It has discovered and developed EKTERLY, an oral on-demand treatment for hereditary angioedema (HAE). EKTERLY is formulated as a film-coated tablet for oral administration, with high bioavailability and selectivity for plasma kallikrein, enabling maximal dosing and a rapid decline in edema effectors that cause swelling during an HAE attack. Its clinical trials include KONFIDENT-KID, KONFIDENT-S and KONFIDENT. KONFIDENT-KID is an open-label clinical trial of sebetralstat for on-demand treatment of HAE attacks in pediatric patients. KONFIDENT-KID collects safety, pharmacokinetic and efficacy data for each patient for up to one year and features a proprietary pediatric orally disintegrating tablet formulation of sebetralstat. KONFIDENT-S study is an open-label extension trial to evaluate the long-term safety of sebetralstat for on-demand treatment of HAE attacks in adolescent and adult patients with type I or type II HAE.
Employees
275
Sector
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
  1. Stock Market
  2. Stocks
  3. KALV Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!